Business Standard

Wednesday, January 29, 2025 | 06:28 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Promoter group to sell 2.53% stake worth $316 million in Cipla: Report

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said

Advertisement
Cipla plans acquisitions to take top spot in South Africa drug market

The company, with a market capitalisation of over $13 billion, is known for making the anti-allergy drug Cetirizine.

Reuters BENGALURU

Listen to This Article

Cipla's promoter group is looking to sell a 2.53% stake in India's third-largest drugmaker via a block deal worth 26.37 billion rupees (nearly $316 million), CNBC-TV18 reported on Tuesday, citing sources.

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said.

The price range of the proposed stake sale means it will be sold at no more than the value of the stock's last closing price, which was 4% lower, at 1,357.35 rupees.

Cipla did not immediately respond to a Reuters request for comment.

The company, with a market capitalisation of over $13 billion, is known for making the anti-allergy drug Cetirizine.

 

Local news media first reported in July 2023 that Cipla's top shareholders were in talks to sell a part of their stake in the company to private equity funds such as Blackstone and Baring Asia.

India's Torrent Pharmaceuticals was in talks with Apollo Global Management to borrow up to $1 billion for a bid to buy a stake in Cipla, Reuters reported last September.

The stake sale plan faced hurdles at the time as the promoters were not in agreement about the common valuation, ET Now had reported.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 14 2024 | 10:17 PM IST

Explore News